Document Detail

One-month serotonin infusion results in a prolonged fall in blood pressure in the deoxycorticosterone acetate (DOCA) salt hypertensive rat.
MedLine Citation:
PMID:  23336053     Owner:  NLM     Status:  MEDLINE    
A 7-day infusion of serotonin (5-hydroxytryptamine, 5-HT) causes a sustained fall in elevated blood pressure in the male deoxycorticosterone acetate (DOCA)-salt rat. As hypertension is a long-term disease, we presently test the hypothesis that a longer (30 day) 5-HT infusion could cause a sustained fall in blood pressure in the established hypertensive DOCA-salt rat. This time period (∼4 weeks) was also sufficient to test whether 5-HT could attenuate the development of DOCA-salt hypertension. 5-HT (25 μg/kg/min; sc) or vehicle (Veh) was delivered via osmotic pump to (1) established DOCA-salt rats for one month, (2) Sprague-Dawley rats prior to DOCA-salt administration for one month, and blood pressure and heart rate measured telemetrically. On the final day of 5-HT infusion, free platelet poor plasma 5-HT concentrations were significantly higher in 5-HT versus Veh-infused rats, and mean arterial pressure was significantly lower in 5-HT-infused (135 ± 4 mmHg vs Veh-infused 151 ± 7 mmHg) established DOCA-salt rats. By contrast, 5-HT-infusion did not prevent the development of DOCA-salt hypertension (144 ± 7 mmHg vs Veh = 156 ± 6 mmHg). Isometric contraction of aortic strips was measured, and neither the potency nor maximum contraction to the alpha adrenergic receptor agonist phenylephrine (PE) or 5-HT were modified by infusion of 5-HT (established or preventative infusion), and maximum aortic relaxation to acetylcholine (ACh) was modestly but not significantly enhanced (∼15% improvement). This study demonstrates 5-HT is capable of lowering blood pressure in established DOCA-salt hypertensive rats over the course of one month in a mechanism that does not significantly modify or is dependent on modified vascular responsiveness. This finding opens the possibility that elevation of 5-HT levels could be useful in the treatment of hypertension.
Robert Patrick Davis; Theodora Szasz; Hannah Garver; Robert Burnett; Nathan R Tykocki; Stephanie W Watts
Related Documents :
24943993 - Relation of epicardial fat to central aortic pressure and left ventricular diastolic fu...
10660193 - Fatigue-induced changes to the biaxial mechanical properties of glutaraldehyde-fixed po...
8681613 - Contribution of lung and chest wall mechanics following emphysema resection.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2012-09-16
Journal Detail:
Title:  ACS chemical neuroscience     Volume:  4     ISSN:  1948-7193     ISO Abbreviation:  ACS Chem Neurosci     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-21     Completed Date:  2013-07-02     Revised Date:  2014-01-23    
Medline Journal Info:
Nlm Unique ID:  101525337     Medline TA:  ACS Chem Neurosci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  141-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / administration & dosage,  pharmacology*
Arterial Pressure / drug effects
Desoxycorticosterone / toxicity
Hypertension / drug therapy*
Infusions, Intravenous
Isometric Contraction / drug effects
Mineralocorticoids / toxicity
Muscle, Smooth, Vascular / drug effects
Rats, Sprague-Dawley
Serotonin / administration & dosage,  pharmacology*
Grant Support
Reg. No./Substance:
0/Antihypertensive Agents; 0/Mineralocorticoids; 333DO1RDJY/Serotonin; 40GP35YQ49/Desoxycorticosterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact wi...
Next Document:  Exploring the role of 5-HT1A receptors in the regulation of prepulse inhibition in mice: implication...